JP6512568B2 - 経皮投与用ｗｔ１ペプチド癌ワクチン組成物 - Google Patents

経皮投与用ｗｔ１ペプチド癌ワクチン組成物 Download PDF

Info

Publication number
JP6512568B2
JP6512568B2 JP2014014802A JP2014014802A JP6512568B2 JP 6512568 B2 JP6512568 B2 JP 6512568B2 JP 2014014802 A JP2014014802 A JP 2014014802A JP 2014014802 A JP2014014802 A JP 2014014802A JP 6512568 B2 JP6512568 B2 JP 6512568B2
Authority
JP
Japan
Prior art keywords
receptor
peptide
receptor agonist
agonist
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014014802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014169277A (ja
Inventor
大久保　勝之
勝之 大久保
佳己 前田
佳己 前田
有道 岡崎
有道 岡崎
大介 浅利
大介 浅利
卓矢 宍戸
卓矢 宍戸
光彦 堀
光彦 堀
治夫 杉山
治夫 杉山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
University of Osaka NUC
Original Assignee
Nitto Denko Corp
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp, Osaka University NUC filed Critical Nitto Denko Corp
Priority to JP2014014802A priority Critical patent/JP6512568B2/ja
Publication of JP2014169277A publication Critical patent/JP2014169277A/ja
Application granted granted Critical
Publication of JP6512568B2 publication Critical patent/JP6512568B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2014014802A 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチン組成物 Expired - Fee Related JP6512568B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014014802A JP6512568B2 (ja) 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013020906 2013-02-05
JP2013020906 2013-02-05
JP2014014802A JP6512568B2 (ja) 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチン組成物

Publications (2)

Publication Number Publication Date
JP2014169277A JP2014169277A (ja) 2014-09-18
JP6512568B2 true JP6512568B2 (ja) 2019-05-15

Family

ID=50028737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014014802A Expired - Fee Related JP6512568B2 (ja) 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチン組成物

Country Status (8)

Country Link
US (1) US10449144B2 (enExample)
EP (1) EP2762159A1 (enExample)
JP (1) JP6512568B2 (enExample)
KR (1) KR20140100419A (enExample)
CN (1) CN103961307B (enExample)
CA (1) CA2841016A1 (enExample)
IN (1) IN2014CH00391A (enExample)
RU (1) RU2687144C2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
EP2868325B1 (en) * 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2945647B1 (en) 2013-01-15 2020-09-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
JP6512569B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
IN2014CH00391A (enExample) 2013-02-05 2015-04-03 Nitto Denko Corp
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
CN106687138B (zh) * 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
TW201618790A (zh) * 2014-10-02 2016-06-01 Nitto Denko Corp 經皮投與用疫苗醫藥組合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
RU2192884C2 (ru) 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
WO2002079253A1 (en) 2001-03-22 2002-10-10 Haruo Sugiyama Wti modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004026897A1 (ja) 2002-09-20 2004-04-01 Chugai Seiyaku Kabushiki Kaisha Ｗｔ１置換型ペプチド
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
PT2071028E (pt) 2003-11-05 2012-04-10 Int Inst Cancer Immunology Inc Péptido antigénico de ligação a hla-dr derivado de wt1
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
JP4931798B2 (ja) 2004-03-15 2012-05-16 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
KR101385805B1 (ko) 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
AU2006321287B2 (en) * 2005-12-01 2013-05-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases
CA2886615A1 (en) 2006-02-22 2007-08-30 International Institute Of Cancer Immunology, Inc. Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP4925039B2 (ja) 2006-09-21 2012-04-25 日東電工株式会社 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
CA2886622A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
ES2989864T3 (es) * 2007-12-05 2024-11-28 Int Inst Cancer Immunology Inc Composición vacunal contra el cáncer
EP2119726B2 (en) * 2008-05-14 2017-11-29 Immatics Biotechnologies GmbH Novel and powerful MHC-class II peptides derived from survivin and neurocan
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011046832A2 (en) 2009-10-12 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Granulysin in immunotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
IN2014CH00391A (enExample) 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
JP6512569B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
RU2014102945A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция
EP2762158A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration

Also Published As

Publication number Publication date
KR20140100419A (ko) 2014-08-14
RU2687144C2 (ru) 2019-05-07
US10449144B2 (en) 2019-10-22
RU2014102936A (ru) 2015-08-10
US20140220055A1 (en) 2014-08-07
EP2762159A1 (en) 2014-08-06
CA2841016A1 (en) 2014-08-05
CN103961307A (zh) 2014-08-06
IN2014CH00391A (enExample) 2015-04-03
JP2014169277A (ja) 2014-09-18
CN103961307B (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
JP6512567B2 (ja) 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
JP6512568B2 (ja) 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
JP6512569B2 (ja) 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
JP6473292B2 (ja) ワクチン組成物
JP2014169280A (ja) 経皮または粘膜投与用ワクチン組成物
JP2014169278A (ja) 経皮投与用ワクチン組成物
EP3189851A1 (en) Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190402

R150 Certificate of patent or registration of utility model

Ref document number: 6512568

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees